On October 9, Royalty management company Theravance, Inc. (NASDAQ:THRX) announced Thursday the appointment of Eric d'Esparbes as senior vice president and the new chief financial officer of the company.
Albany, New York (10/01/2014) - Theravance Inc (NASDAQ:THRX) is trading near its 52-week lows around $17.09. In the month of September, it announced the key updates on its proprietary FDA-approved product VIBATIV�.
Theravance Inc (NASDAQ:THRX) finished last trade at $17.06, gaining +1.79%. Trading volume recorded for this company was about 1.92 million shares as compared to its average volume of 0.708 million shares.